Menon Shina, Krallman Kelli A, Arikan Ayse A, Fuhrman Dana Y, Gorga Stephen M, Mottes Theresa, Ollberding Nicholas, Ricci Zaccaria, Stanski Natalja L, Selewski David T, Soranno Danielle E, Zappitelli Michael, Zang Huaiyu, Gist Katja M
Department of Pediatrics, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, Washington, USA.
Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Kidney Int Rep. 2023 Jun 5;8(8):1542-1552. doi: 10.1016/j.ekir.2023.05.026. eCollection 2023 Aug.
Continuous renal replacement therapy (CRRT) is used for the symptomatic management of acute kidney injury (AKI) and fluid overload (FO). Contemporary reports on pediatric CRRT are small and single center in design. Large international studies evaluating CRRT practice and outcomes are lacking. Herein, we describe the design of a multinational collaborative.
The Worldwide Exploration of Renal Replacement Outcomes Collaborative in Kidney Disease (WE-ROCK) is an international collaborative of pediatric specialists whose mission is to improve short- and long-term outcomes of children treated with CRRT. The aims of this multicenter retrospective study are to describe the epidemiology, liberation patterns, association of fluid balance and timing of CRRT initiation, and CRRT prescription with outcomes.
We included children ( = 996, 0-25 years) admitted to an intensive care unit (ICU) and treated with CRRT for AKI or FO at 32 centers (in 7 countries) from 2018 to 2021. Demographics and clinical characteristics before CRRT initiation, during the first 7 days of both CRRT, and liberation were collected. Outcomes include the following: (i) major adverse kidney events at 90 days (mortality, dialysis dependence, and persistent kidney dysfunction), and (ii) functional outcomes (functional stats scale).
The retrospective WE-ROCK study represents the largest international registry of children receiving CRRT for AKI or FO. It will serve as a broad and invaluable resource for the field of pediatric critical care nephrology that will improve our understanding of practice heterogeneity and the association of CRRT with clinical and patient-centered outcomes. This will generate preliminary data for future interventional trials in this area.
连续性肾脏替代治疗(CRRT)用于急性肾损伤(AKI)和液体超负荷(FO)的症状管理。当代关于儿科CRRT的报告规模较小且为单中心设计。缺乏评估CRRT实践和结局的大型国际研究。在此,我们描述一项多国合作研究的设计。
全球肾脏疾病肾脏替代治疗结局探索协作组(WE-ROCK)是一个儿科专家的国际合作组织,其使命是改善接受CRRT治疗儿童的短期和长期结局。这项多中心回顾性研究的目的是描述流行病学、撤机模式、液体平衡与CRRT开始时间的关联,以及CRRT处方与结局的关系。
我们纳入了2018年至2021年在32个中心(分布于7个国家)的重症监护病房(ICU)住院并因AKI或FO接受CRRT治疗的儿童(n = 996,0至25岁)。收集了CRRT开始前、CRRT的前7天以及撤机期间的人口统计学和临床特征。结局包括:(i)90天时的主要不良肾脏事件(死亡率、透析依赖和持续性肾功能不全),以及(ii)功能结局(功能状态量表)。
回顾性的WE-ROCK研究是接受CRRT治疗的AKI或FO儿童的最大规模国际登记研究。它将成为儿科重症监护肾脏病领域广泛且宝贵的资源,有助于我们了解实践的异质性以及CRRT与临床和以患者为中心的结局之间的关联。这将为该领域未来的干预试验提供初步数据。